Endocrine Treatment of Male-to-Female Transsexuals Using Gonadotropin-Releasing Hormone Agonist

Abstract

In transsexual people, cross-sex hormone therapy is an important component of medical treatment. In male-to-female transsexuals, feminizing effects should be achieved before irreversible sex reassignment surgery (SRS) is considered. The most common treatment regimen in male-to-female transsexuals is a combination of ethinyl oestradiol and cyproterone acetate, with the exception of transdermal oestradiol-17β in individuals over the age of 40. The mortality and morbidity rates with this treatment regimen have been reported in more than 800 patients. Typical side effects include venous thrombosis, elevated liver enzymes, symptomatic gallstones, hyperprolactinaemia and depression. Sixty male-to-female transsexuals were treated with monthly injections of gonadotropin-releasing hormone agonist (GnRHa) and oral oestradiol-17β valerate for 2 years to achieve feminisation until SRS. There was a significant decline in gonadotropins, total testosterone and calculated free testosterone. In general, the treatment regimen was well accepted. An equal increase in breast size was achieved compared to common hormone therapy. Two side effects were documented. One, venous thrombosis, occurred in a patient with a homozygous MTHFR mutation. One patient was found to be suffering from symptomatic preexisting gallstones. No other complications were documented. Liver enzymes, lipids, and prolactin levels were unchanged. Significantly increased oestradiol and SHBG serum levels were detectable. In addition, an increase in bone mass density, in the femoral neck and lumbar spine, was recorded. We conclude that cross-sex hormone treatment of male-to-female transsexuals using GnRHa and oestradiol-17β valerate is effective, and side effects and complication rates can be reduced using the treatment regimen presented here.

Transsexuals - GnRH analogues - cross-sex hormone treatment

References

• 1 Adlercreutz H, Tenhunen R. Some aspects of the interaction between natural and synthetic female sex hormones and the liver.  Am J Med. 1970;  49 630-648
• 2 Aedo A R, Landgren B M, Diczfalusy E. Pharmacokinetics and biotransformation of orally administered oestrone sulphate and oestradiol valerate in postmenopausal women.  Maturitas. 1990;  12 333-343
• 3 Aldinger K, Ben Menachem Y, Whalen G. Focal nodular hyperplasia of the liver associated with high-dosage estrogens.  Arch Intern Med. 1977;  137 357-359
• 4 Anderson G L, Limacher M, Assaf A R, Bassford T, Beresford S A, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard B V, Hsia J, Hubbell A, Jackson R, Johnson K C, Judd H, Kotchen J M, Kuller L, LaCroix A Z, Lane D, Langer R D, Lasser N, Lewis C E, Manson J, Margolis K, Ockene J, O'Sullivan M J, Phillips L, Prentice R L, Ritenbaugh C, Robbins J, Rossouw J E, Sarto G, Stefanick M L, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S. Women's Health Initiative Steering Committee . Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.  J Am Med Assoc. 2004;  291 1701-1712
• 5 Asscheman H, Gooren L, Assies J, Smith J, De Slegte R. Prolactin levels and pituitary enlargement in hormone-treated male to female transsexual people.  Clin Endocrinol (Oxford). 1988;  28 583-588
• 6 Asscheman H, Gooren L, Eklund P. Mortality and morbidity in transsexual patients with cross-gender hormone treatment.  Metabolism. 1989;  38 869-873
• 7 Berrut G, Ghali A, Quere I, Ternisien C, Gallois I, Roy P M, Marre M, Fressinaud P. A common mutation C677 T in the 5,10-methyltetrahydrofolate reductase gene is associated to idiopathic deep venous thrombosis.  Revue de Médecine Interne. 2003;  24 569-576
• 8 Cushman M, Kuller L H, Prentice R, Rodabough R J, Psaty B M, Stafford R S, Sidney S, Rosendaal F R. Women's Health Initiative Investigators . Estrogen plus progestin and risk of venous thrombosis.  J Am Med Assoc. 2004;  292 1573-1580
• 9 den Heijer M. Hyperhomocysteinaemia as a risk factor for venous thrombosis: an update of the current evidence.  Clinical Chemistry and Laboratory Medicine CCLM/FESCC. 2003;  41 1404-1407
• 10 Futterweit W. Endocrine management of transsexual: hormonal profiles of serum prolactin, testosterone, and estradiol.  New York State J Medicine. 1980;  80 1260-1264
• 11 Gooren L, Assies J, Asscheman H, de Slegte R, van Kessel H. Estrogen-induced prolactinoma in a man.  J Clin Endocrinol Metab. 1988;  66 444-446
• 12 Hamburger C. Endocrine treatment of male and female transsexualism. Green R, Money J Transsexualism and Sex Reassignment. Baltimore; Johns Hopkins Press 1969: 291-307
• 13 Hannaford P, Croft P, Kay C. Oral contraception and stroke.  Stroke. 1994;  25 935-942
• 14 Harry Benjamin International Gender Dysphoria Association .The Harry Benjamin International Gender Dysphoria Association standards of care for gender identity disorders. 6th version (November 17th, 2001). http://www.hbigda.org/soc.html. Retrieved 2002. 
• 15 Kacar S, Akdogan M, Kosar Y, Parlak E, Sasmaz N, Oguz P, Aydog G. Estrogen and cyproterone acetate combination-induced autoimmune hepatitis.  J Clin Gastroenterol. 2002;  35 98-100
• 16 Khosla S, Melton 3rd L J. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen.  J Clin Endocrinol Metab. 1998;  83 2266-2274
• 17 Kuhl H. Pharmacology of estradiol and estriol.  Menopause Rev. 2000;  5 23-44
• 18 Levy A, Crown A, Reid R. Endocrine intervention for transsexuals.  Clin Endocrinol. 2003;  59 409-418
• 19 Lin A D, Chen K K, Lin A T, Chang Y H, Wu H H, Kuo J Y, Huang W J, Hsu Y S, Chung H J, Chang L S. Antiandrogen-associated hepatotoxicity in the management of advanced prostate cancer.  J Chinese Med Assoc. 2003;  66 735-740
• 20 Meyer W JR, Webb A, Stuart C A, Finkelstein J W, Lawrence B, Walker P A. Physical and hormonal evaluation of transsexual patients: a longitudinal study.  Arch Sexual Behavior. 1986;  15 121-138
• 21 Michel A, Mormont C, Legros J. A psycho-endocrinological overview of transsexualism.  Eur J Endocrinol. 2001;  145 365-376
• 22 Miyaji Y, Saika T, Yamamoto Y, Kusaka N, Arata R, Ebara S, Nasu Y, Tsushima T, Kumon H. Effects of gonadotropin-releasing hormone agonists on bone metabolism markers and bone mineral density in patients with prostate cancer.  Urology. 2004;  64 128-131
• 23 Moore E, Wisniewski A, Dobs A. Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects.  J Clin Endocrinol Metab. 2003;  88 3467-3473
• 24 Ongphiphadhanakul B, Rajatanavin R, Chanprasertyothin S, Piaseu N, Chailurkit L. Serum oestradiol and oestrogen-receptor gene polymorphism are associated with bone mineral density independently of serum testosterone in normal males.  Clin Endocrinol. 1998;  49 803-809
• 25 Rosing J, Curvers J, Tans G. Oral contraceptives, thrombosis and haemostasis.  Eur J Obstet Gynecol Reprod Biol. 2001;  95 193-197
• 26 Rossouw J E, Anderson G L, Prentice R L, LaCroix A Z, Kooperberg C, Stefanick M L, Jackson R D, Beresford S A, Howard B V, Johnson K C, Kotchen J M, Ockene J. Writing Group for the Women's Health Initiative Investigators . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial.  J Am Med Assoc. 2002;  288 321-333
• 27 Schlatterer K, Auer D P, Yassouridis A, von Werder K, Stalla G K. Transsexualism and osteoporosis.  Exp Clin Endocrinol Diabetes. 1998;  106 365-368
• 28 Slemenda C W, Longcope C, Zhou L, Hui S L, Peacock M, Johnston C C. Sex steroids and bone mass in older man: positive associations with serum estrogens and negative associations with androgens.  J Clin Invest. 1997;  100 1755-1759
• 29 Smith M R. Management of treatment-related osteoporosis in men with prostate cancer.  Cancer Treatment Reviews. 2003;  29 211-218
• 30 Smith M R, Fallon M A, Lee H, Finkelstein J S. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial.  J Clin Endocrinol Metab. 2004;  89 3841-3846
• 31 Stadel B V. Oral contraceptives and cardiovascular disease.  New Engl J Med. 1981;  305 612-618 672-677
• 32 Tans G, Bouma B N, Buller H R, Rosing J. Changes of hemostatic variables during oral contraceptive use.  Sem Vascular Med. 2003;  3 61-68
• 33 Toorians A W, Thomassen M C, Zweegman S, Magdeleyns E J, Tans G, Gooren L J, Rosing J. Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people.  J Clin Endocrinol Metab. 2003;  88 5723-5729
• 34 Townsend M F, Sanders W H, Northway R O, Graham Jr S D. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma.  Cancer. 1997;  79 545-550
• 35 Van Kesteren P. Recent advances in gender dysphoria. Paper presented at a conference of the Royal Society of Medicine Sexual Health and Reproductive Medicine Section 2002; London: 16 April 2002. 
• 36 Van Kesteren P, Lips P, Deville W, Popp-Snijders C, Asscheman H, Megens J, Gooren L. The effect of one-year cross-sex hormonal treatment on bone metabolism and serum insulin-like growth factor-1 in transsexuals.  J Clin Endocrinol Metab. 1996;  81 2227-2232
• 37 Van Kesteren P, Asscheman H, Megens J, Gooren L. Mortality and morbidity in transsexual subjects treated with cross-sex hormones.  Clin Endocrinol (Oxford). 1997;  47 337-342
• 38 Van Kesteren P, Lips P, Gooren L J, Asscheman H, Megens J. Long-term follow-up of bone mineral density and bone metabolism in transsexuals treated with cross-sex hormones.  Clin Endocrinol (Oxford). 1998;  48 347-354
• 39 Vermeulen A, Verdonck L, Kaufmann J M. A critical evaluation of simple methods for the estimation of free testosterone in serum.  J Clin Endocrinol Metab. 1999;  84 3666-3672
• 40 Vermeulen A, Kaufman J M, Goemaere S, van Pottelberg I. Estradiol in elderly men.  Aging Male. 2002;  5 98-102
• 41 Ylostalo P, Laakso L, Viinikka L, Ylikorkala O, Vihko R. Cyproterone acetate in the treatment of hirsutism.  Acta Obstetricia Gynecologica Scandinavica. 1981;  60 399-401

1 Ralf Dittrich and Helge Binder contributed equally to the authorship.